Screenshot 2021-01-24 at 7.15.32 PM
Sunday, March 15, 2026
23.6
C
Bengaluru
Hot topics
Patient Centered Pharma – Pipe Dream or Possible?
To me, patient centricity is as fascinating a concept as it is contradictory. It is fascinating because it puts power into the hands of the patient. And it is contradictory because pharma does not like giving away power over its messages or processes. Pharma has traditionally never enjoyed interaction and has depended on ‘pushing’ messages across rather than having ‘conversations’. It probably also explains why we make do with medical reps who are not the sharpest knives in the drawer and scarcely invest in sharpening them.
Define and Measure Digital – KPIs and ROI
Measurement and optimization for digital marketing is one of...
Healthcare is First a Responsibility…
Patient Centricity, the most talked, least understood and poorly implemented strategy in our domain, if holistically approached and sincerely implemented, can truly transform and lead us towards a culture of ‘Healthcare is a Responsibility’. If every person in the life sciences organization at every level, is motivated, trained and equipped to understand, what is of value to the Patient and then strive towards co-creating, creating or contributing, we can travel a huge distance. Is this ‘Value’ paradigm implementable? Well, some are already doing it...
7 Transitions in Leadership for Indian Pharma Leaders
The rapid pace of change, which began in 2020...
Sales Readiness For Trainers and Reps – Improve Effectiveness In A New Pharma World
Last week, I was in a meeting with the...
The West Plays Precision Poker with High-stakes Specialty Drugs while India Plays Volume Chess with Portfolio Resilience
A recent industry spotlight by Venkat Mutavi notes a...
IPM Powers Ahead in 2026: 11% Growth Fueled by Cardiac, Anti-Diabetics, and GLP-1 Stars
India's pharmaceutical market charged into 2026 with strong momentum,...
When Biology Beats Willpower: The Rise of GLP‑1/GIP Therapies
“Lifestyle advice often asks patients to fight powerful evolutionary...
The West Plays Precision Poker with High-stakes Specialty Drugs while India Plays Volume Chess with Portfolio Resilience
A recent industry spotlight by Venkat Mutavi notes a...
IPM Powers Ahead in 2026: 11% Growth Fueled by Cardiac, Anti-Diabetics, and GLP-1 Stars
India's pharmaceutical market charged into 2026 with strong momentum,...
When Biology Beats Willpower: The Rise of GLP‑1/GIP Therapies
“Lifestyle advice often asks patients to fight powerful evolutionary...
The West Plays Precision Poker with High-stakes Specialty Drugs while India Plays Volume Chess with Portfolio Resilience
A recent industry spotlight by Venkat Mutavi notes a...
IPM Powers Ahead in 2026: 11% Growth Fueled by Cardiac, Anti-Diabetics, and GLP-1 Stars
India's pharmaceutical market charged into 2026 with strong momentum,...
When Biology Beats Willpower: The Rise of GLP‑1/GIP Therapies
“Lifestyle advice often asks patients to fight powerful evolutionary...
The West Plays Precision Poker with High-stakes Specialty Drugs while India Plays Volume Chess with Portfolio Resilience
A recent industry spotlight by Venkat Mutavi notes a...
IPM Powers Ahead in 2026: 11% Growth Fueled by Cardiac, Anti-Diabetics, and GLP-1 Stars
India's pharmaceutical market charged into 2026 with strong momentum,...
When Biology Beats Willpower: The Rise of GLP‑1/GIP Therapies
“Lifestyle advice often asks patients to fight powerful evolutionary...
Hot topics
Track and Trace: Indian Pharma – Current and Future Applicability
Pharmaceutical companies must contend with challenges from supply chain lapses (theft, diversion, S.O.P. deviations, product recalls, reverse logistics etc.) counterfeiting and stringent regulations. These challenges get compounded when dealing across the states and country business operations, besides that not only impact tangible profits but also the intangible brand credibility. In this context, there is also a credible increase in public awareness about the genuineness of medicine (in particular medicine that require cold chain) and their predictability of clinical outcomes.
Providing visibility and full traceability becomes a paramount importance to both the Industry and the Govt. – A fool proof solution not only brings transparency in the system, but can also be a key differentiator, and undoubtedly can create immense opportunities for a competitive advantage.
Pharma GCCs in India — Hype, Reality & What’s Next?
Part 1: Pharma GCCs in India — Orange Markets...
Bring Your Own Learning
Articles by K. Hariram, Vivek Hattangadi, DigiPharmaX, Satya Mahesh, Ajesh Shah and Phanish Chandra
The Uncomfortable Truth about Indian Generics: Untangling the Conundrum
India’s pharmaceutical industry occupies a unique and powerful position...
Crafting a Digital Strategy: The Roadmap for 2021
In many situations, technology upgradation is often construed as digital transformation. In a recently conducted survey by Altimeter, 88% of companies said that they were undergoing ‘digital transformation’ but only 25% said that they did so with the purpose beyond investing in new technology. The real definition of digital transformation is the realignment of, or new investment in technology, business models, and processes to create value for customers in a dynamic digital economy.
The West Plays Precision Poker with High-stakes Specialty Drugs while India Plays Volume Chess with Portfolio Resilience
A recent industry spotlight by Venkat Mutavi notes a...
IPM Powers Ahead in 2026: 11% Growth Fueled by Cardiac, Anti-Diabetics, and GLP-1 Stars
India's pharmaceutical market charged into 2026 with strong momentum,...
When Biology Beats Willpower: The Rise of GLP‑1/GIP Therapies
“Lifestyle advice often asks patients to fight powerful evolutionary...
The West Plays Precision Poker with High-stakes Specialty Drugs while India Plays Volume Chess with Portfolio Resilience
A recent industry spotlight by Venkat Mutavi notes a...
IPM Powers Ahead in 2026: 11% Growth Fueled by Cardiac, Anti-Diabetics, and GLP-1 Stars
India's pharmaceutical market charged into 2026 with strong momentum,...
When Biology Beats Willpower: The Rise of GLP‑1/GIP Therapies
“Lifestyle advice often asks patients to fight powerful evolutionary...
The West Plays Precision Poker with High-stakes Specialty Drugs while India Plays Volume Chess with Portfolio Resilience
A recent industry spotlight by Venkat Mutavi notes a...
IPM Powers Ahead in 2026: 11% Growth Fueled by Cardiac, Anti-Diabetics, and GLP-1 Stars
India's pharmaceutical market charged into 2026 with strong momentum,...
When Biology Beats Willpower: The Rise of GLP‑1/GIP Therapies
“Lifestyle advice often asks patients to fight powerful evolutionary...
The West Plays Precision Poker with High-stakes Specialty Drugs while India Plays Volume Chess with Portfolio Resilience
A recent industry spotlight by Venkat Mutavi notes a...
IPM Powers Ahead in 2026: 11% Growth Fueled by Cardiac, Anti-Diabetics, and GLP-1 Stars
India's pharmaceutical market charged into 2026 with strong momentum,...
When Biology Beats Willpower: The Rise of GLP‑1/GIP Therapies
“Lifestyle advice often asks patients to fight powerful evolutionary...
MedicinMan was launched in 2011 as India’s 1st Magazine dedicated to the cause of Field Force Excellence in Pharma and Devices.
Read More
Headlines
The West Plays Precision Poker with High-stakes Specialty Drugs while India Plays Volume Chess with Portfolio Resilience
A recent industry spotlight by Venkat Mutavi notes a...
IPM Powers Ahead in 2026: 11% Growth Fueled by Cardiac, Anti-Diabetics, and GLP-1 Stars
India's pharmaceutical market charged into 2026 with strong momentum,...
Newsletter
Get important news delivered directly to your inbox and stay connected!